Alzheimer's disease

Enhanced Genomics’ 3D multi-omics platform harnessed to rapidly identify multiple novel therapeutic targets that were undetectable using conventional genomic approaches

Galimedix has recruited people with dry AMD to test the efficacy of their drug, which disrupts the same toxic beta-amyloid oligomers implicated in Alzheimer’s disease.

Insights from the AD/PD meeting, continued fallout from the FDA layoffs, hope for GLP-1 drugs in Alzheimer’s disease, and more led industry news this week.

A landmark UTI drug approval, new hope for the amyloid hypothesis in Alzheimer’s disease, a brewing vaccine study controversy, and more led the news this week.

DDN editors break down a surprising connection between microplastics and antimicrobial resistance, vitamin D for multiple sclerosis, obesity drugs updates, and more news from this week.

New gene therapies in clinical trials seek to treat Alzheimer’s disease and heal the brain with a dose of helpful genetic material.

By watching brain organoids develop, researchers observed surprising abnormalities caused by mutations in a gene related to early-onset Alzheimer’s disease.

Young blood rejuvenates aging organs in rodents. Researchers are studying the potential to use young blood-based treatments in aging humans too.

Activating specific neurons using light helped scientists establish a causal link between improved sleep and diminished signs of Alzheimer’s disease in mice.

Slight modifications to glycoproteins reveal critical insights into disease onset, state, and progression, making them a wellspring for biomarker discovery.